Lisa Williams, APRN
Nurse Practitioner · Bedford, NHNPI 1396799169
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.6% of the total across 268 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 268 payments — averaging $27.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Alkermes, Inc.$817
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$717
- Teva Pharmaceuticals USA, Inc.$569
- Axsome Therapeutics, Inc.$513
- Johnson & Johnson$483
- plus $3K from 15 others
What the payments were for
- Travel & lodging$2433%
- Food & beverage$6,86395%
- Education$1492%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 75 | $1,412 |
| Alkermes, Inc. | 21 | $817 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 22 | $717 |
| Teva Pharmaceuticals USA, Inc. | 21 | $569 |
| Axsome Therapeutics, Inc. | 5 | $513 |
| Johnson & Johnson | 17 | $483 |
| Otsuka America Pharmaceutical, Inc. | 20 | $452 |
| Neuronetics, Inc. | 3 | $398 |
| Eisai Inc. | 5 | $380 |
| Neurocrine Biosciences, Inc. | 9 | $368 |
| Lundbeck LLC | 17 | $335 |
| E.r. Squibb & Sons, L.L.C. | 9 | $196 |
| Ironshore Pharmaceuticals Inc. | 8 | $160 |
| Sunovion Pharmaceuticals Inc. | 22 | $143 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $97 |
| Collegium Pharmaceutical, Inc. | 3 | $64 |
| Vanda Pharmaceuticals Inc. | 3 | $48 |
| Supernus Pharmaceuticals, Inc. | 1 | $38 |
| Luye Pharma (USA) Ltd. | 1 | $27 |
| Braeburn Inc. | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auvelity$482
- VRAYLAR$461
- LYBALVI$418
- ARISTADA$407
- NEUROSTAR TMS THERAPY SYSTEM$398
- INGREZZA$237
- CAPLYTA$113
- SPRAVATO$106
- Austedo XR$103
- ARISTADA INITIO$102
How this compares
$7,255 in reported general payments places this provider in the 95th percentile of 714 nurse practitioner providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 28 | $310,436 |
| VraylarCariprazine Hcl | 55 | $99,966 |
| Invega SustennaPaliperidone Palmitate | 21 | $69,628 |
| RexultiBrexpiprazole | 15 | $26,019 |
| Lurasidone Hcl | 58 | $16,507 |
| Lisdexamfetamine Dimesylate | 46 | $11,959 |
| TrintellixVortioxetine Hydrobromide | 23 | $11,621 |
| Aripiprazole | 108 | $11,388 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 257 | $10,600 |
| VyvanseLisdexamfetamine Dimesylate | 15 | $8,233 |
| Bupropion XlBupropion Hcl | 232 | $7,749 |
| AdderallDextroamphetamine/Amphetamine | 13 | $7,563 |
| Paliperidone ErPaliperidone | 17 | $6,252 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 70 | $5,567 |
| Oxcarbazepine | 80 | $4,646 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $569 | $310,43628 claims |
| AbbVieVraylar | $1,412 | $99,96655 claims |
| Johnson & JohnsonInvega Sustenna | $483 | $69,62821 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse, Adderall | $97 | $27,41751 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $452 | $26,01915 claims |
| Eisai Inc.Dayvigo | $380 | $4,57013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 714 nurse practitioner providers in New Hampshire.
Other nurse practitioner in Bedford
- Jessica St JeanPelham$302K
- Michael RobustelliSomersworth$17K
- Denise McGrathLebanon$7K
- Shareen LucasPortsmouth$7K
- Sonya AlyeaSomersworth$6K
- Jessica PollackConcord$5K
- Jennifer GriffinNashua$5K
- Dawne HillsgroveNashua$4K
- Shelby MenardSomersworth$4K
- Alexandra RobertsRochester$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.